EP1.03-32 Prevalence of EGFR and ALK Mutations in Non Small Cell Lung Cancer in Viet Nam National Cancer Hospital

Abstract

A significant percentage of non small cell lung cancer (NSCLC) have driver mutations. Epidermal growth factor receptor (EGFR) mutations and anaplastic large-cell lymphoma kinase (ALK) rearrangements are now routine biomarkers that have been incorporated into the practice of managing NSCLC. To date, there has been no assessment of the prevalence of these mutations in NSCLC in Viet Nam National Cancer Hospital. The prospective study of formalin fixed paraffin embedded (FFPE) tissues from patients diagnosed with NSCLC was performed to assess the prevalence of EGFR and ALK mutations in NSCLC in Viet Nam National Cancer Hospital. Patients with NSCLC in Viet Nam National Cancer Hospital were prospectively enrolled. FFPE tissue samples were tested for EGFR mutation by PCR and for EML4-ALK translocation by fluorescence in situ hybridization (FISH) A total of 103 patients were enrolled, 78 (76.7%) males and 25 females (23.3%), with a mean age of 57.7 years. Adenocarcinoma and Squamous cell carcinoma rate were 89.3% and 10.7%, respectively. EGFR testing of 103 patients (100%) demonstrated the wild type in 76 (73.8%) and mutated forms in 27 (26.2%). Some 74.0% of EGFR positive patients were non-smokers and 44.4% were females. Regarding the EML4-ALK translocation, testing in 103 cases (100%) gave positive results in only 11 (10.7%). Among 11 patients with EML4-ALK translocation, 6 patients (54.5 %) were females and 6 patients (54.5 %) were smokers. Moreover, only two squamous cell carcinoma patients had positive EGFR mutation and only one patient had concurrent EGFR mutation and ALK rearrangement In this sudy investigating the prevalence of EGFR and ALK mutations in non small cell lung cancer in Vietnam National Cancer Hospital, 26.2% had EGFR mutation and 10.7% had ALK translocation mutations, as compared to 35% and 6.1%, respectively, in Asian